Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

ogress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

According to the National Multiple Sclerosis Society, approximately 400,000 Americans acknowledge having MS, and every week about 200 people are diagnosed. Worldwide, multiple sclerosis may affect 2.5 million individuals.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indication in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adv
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... DUBLIN , June 1, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/qrmgrq/_analysis_of_the ) has announced the addition of ... Image Displays Market" report to their ... ,This report provides an in-depth analysis of ... revenue forecast, market shares, market dynamics, and ...
(Date:6/1/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced data ... in a Phase 1 investigator-sponsored study at the University ... presented at the 2015 American Society of Clinical Oncology ... Results from this study show a tolerable safety ... given intravenously.  Based in part on the ...
(Date:6/1/2015)... June 1, 2015 The Middle Eastern MRI systems ... which is replacing CT because of its higher sensitivity and ... one between the two available systems of MRI, open and ... top and bottom and do not enclose the patient in ... a study which shows that one in every 6 patients ...
Breaking Medicine Technology:Analysis of the US Medical Image Displays Market 2015-2017 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Middle East Open System MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2
... the,symptoms of thyroid disease for another disorder such ... a new edition of a report from,Harvard Medical ... particularly in older men and women, that doctors ... focus on common,illnesses that occur with age, according ...
... /Xinhua-PRNewswire/ -- TaiGen Biotechnology,Inc. announces the successful completion ... clinical trial of Nemonoxacin (TG-873870) for,the treatment of ... have been admitted to the trial. Completion of ... quarter of 2007. In this trial, the effect,of ...
Cached Medicine Technology:You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report 2TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP) 2
(Date:6/2/2015)... June 02, 2015 TheCelebrityDresses.com, a popular ... big discounts on their summer fashion cocktail dresses. The ... short dresses that would be suitable for a wide ... , TheCelebrityDresses.com designs and make high quality trendy ... they use include high quality satin, chiffon and cotton. ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The ... a study from the RSSearch® Patient Registry evaluating ... body radiotherapy (SBRT) for the treatment of centrally ... lung metastases. , The study, published in ... http://www.ro-journal.com/content/10/1/113/abstract ), included 111 patients with 114 centrally ...
(Date:6/2/2015)... Robert LaPrade, MD, PhD, Colorado Knee ... Research Institute, participated in the study “ When ... This was a collaborative project from the American Orthopaedic ... recently published in the American Journal of Sports Medicine. ... is evidence that early sport specialization may put young ...
(Date:6/2/2015)... Each year, Cosmetic Executive Women (CEW) awards ... year, the organization’s members – 8,000 industry experts – ... Beauty Quest Award at the 2015 Beauty Insiders’ Choice ... and 2-in-1 approach to skincare differentiated it amongst a ... consumer and professional fan bases, QVC has awarded Scalisi ...
(Date:6/2/2015)... 2015 SB 277 (CA Legislature, bit.ly/1Q0P8OY) ... to attend public or private school. SB277 cleared three ... the Appropriations Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). ... , “We believe that this bill affects the ... than it will (the) affect public health of California.. ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2
... 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC ... pharmaceutical, medicinal and diagnostic products in China,today announced ... to,the Company,s Form 10KSB for the year 2006. ... Form 10QSB for the three, six and nine ...
... COMPANY REPORTS PROGRESS ON KEY INITIATIVES, RANCHO CORDOVA, ... a leading supplier of innovative products and,services that process, ... treatment of disease and injury, today reported results for,the ... quarter ended September 30, 2007, were $3.6 million,compared with ...
... OWINGS MILLS, Md., Nov. 8 Medifast, Inc.,(NYSE: ... the period ended,September 30, 2007. For quarter-ended September 30, ... from $19.6 million in the third,quarter of 2006. The ... share ($0.07 per diluted share), versus $1,455,000 or $0.11 ...
... ESAs can increase cancer growth, cause stroke and heart ... News) -- The U.S. Food and Drug Administration on ... erythropoiesis-stimulating agents, which are drugs used to treat certain ... Aranesp, Epogen and Procrit, and detail their dangers to ...
... N.J., Nov. 8 Wyeth (NYSE: WYE ),announced ... First Boston,Healthcare Conference on Tuesday, November 13, 2007 at ... M. Mahady, Senior Vice President,Wyeth and President, Wyeth Pharmaceuticals ... for investors at, http://www.wyeth.com and available for replay ...
... CLEVELAND, Nov. 8 Medical Mutual and Ohio ... to provide quality,affordable health insurance to OFBF,s more ... Farm Bureau members will gain access to,Medical Mutual,s ... hospitals and other medical service providers in Ohio. ...
Cached Medicine News:Health News:China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 2Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 3Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 4Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 5Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 6Health News:ThermoGenesis Corp. Reports First Quarter 2008 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 2Health News:Medifast Announces Third-Quarter 2007 Results 3Health News:Medifast Announces Third-Quarter 2007 Results 4Health News:Medifast Announces Third-Quarter 2007 Results 5Health News:Medifast Announces Third-Quarter 2007 Results 6Health News:Medifast Announces Third-Quarter 2007 Results 7Health News:Medifast Announces Third-Quarter 2007 Results 8Health News:FDA Issues New Warnings for Anemia Drugs 2Health News:FDA Issues New Warnings for Anemia Drugs 3Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Pocket-sized instrument with fiber optic illumination. Swivelling viewing window with 3X magnification....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: